Notice of Clarification to Award Information in RFA-AI-20-020 “Tuberculosis Research Units (U19 Clinical Trial Optional)”

Notice Number: NOT-AI-20-049

Key Dates
Release Date: May 05, 2020

Related Announcements

RFA-AI-20-020

Issued by
National Institute of Allergy and Infectious Diseases (NIAID)

Purpose

The purpose of this Notice is to clarify the award information in RFA-AI-20-020 “Tuberculosis Research Units (U19 Clinical Trial Optional).”

Through this Notice, the following change has been made:


Part 2. Full Text of Announcement

Section II. Award Information


Currently reads:

Funding Instrument

Cooperative Agreement: A support mechanism used when there will be substantial Federal scientific or programmatic involvement. Substantial involvement means that, after award, NIH scientific or program staff will assist, guide, coordinate, or participate in project activities. See Section VI.2 for additional information about the substantial involvement for this FOA.

Application Types Allowed

New
Renewal

The OER Glossary and the SF424 (R&R) Application Guide provide details on these application types. Only those application types listed here are allowed for this FOA.

Clinical Trial?

Optional: Accepting applications that either propose or do not propose clinical trial(s)

Need help determining whether you are doing a clinical trial?

Funds Available and Anticipated Number of Awards

NIAID intends to commit $10 million in FY 2020 to fund 2-3 awards.

Award Budget

Applicants may propose a recommended budget of up to $1.8 million per year in direct costs.

Award Project Period

The scope of the proposed project should determine the project period. The maximum project period is 5 years.

NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this FOA.


Revised to read:

Funding Instrument

Cooperative Agreement: A support mechanism used when there will be substantial Federal scientific or programmatic involvement. Substantial involvement means that, after award, NIH scientific or program staff will assist, guide, coordinate, or participate in project activities. See Section VI.2 for additional information about the substantial involvement for this FOA.

Application Types Allowed

New
Renewal

The OER Glossary and the SF424 (R&R) Application Guide provide details on these application types. Only those application types listed here are allowed for this FOA.

Clinical Trial?

Optional: Accepting applications that either propose or do not propose clinical trial(s)

Need help determining whether you are doing a clinical trial?

Funds Available and Anticipated Number of Awards

NIAID intends to commit $10 million in FY 2021 to fund 2-3 awards.

Award Budget

Applicants may propose a recommended budget of up to $1.8 million per year in direct costs.

Award Project Period

The scope of the proposed project should determine the project period. The maximum project period is 5 years.

NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this FOA.


All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Susana Mendez, DVM, PhD
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: 240-669-5077
Email: mendezs@mail.nih.gov